Home›Stock Screener›Tatva Chintan Pharma›Quarterly Results

Tatva Chintan Pharma Quarterly Results

Latest Quarter Net Profit
₹10 Cr
QMar 2026
Quarterly Results

Tatva Chintan Pharma quarterly results. In Mar 2026, Tatva Chintan Pharma (TATVA) reported revenue ₹134 Cr and net profit ₹10 Cr — revenue +22.9% YoY. Review TATVA P/E comparison to evaluate earnings-based valuation against sector peers.

TATVA Quarterly Results — Revenue, Profit & EPS Highlights

Tatva Chintan Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit TATVA stock price BSE.

  • Revenue of ₹134 Cr in Mar 2026 (-21.2% vs Jun 2026, +22.9% vs Mar 2025)
  • Net Profit of ₹10 Cr in Mar 2026 (-37.5% vs Jun 2026, +900.0% vs Mar 2025)
  • EBITDA of ₹28 Cr in Mar 2026 (-17.6% vs Jun 2026)
  • Operating Margin of 21.0% in Mar 2026 (+2.0pp vs Jun 2026)
  • Earnings Per Share of ₹4.41 in Mar 2026 (-35.4% vs Jun 2026)

Tatva Chintan Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

TATVA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 134 170 125 109 118 -21.2% 22.9%
Net Profit (₹ Cr) 10 16 10 1 7 - -
EBITDA (₹ Cr) 28 34 23 10 19 - -
EPS (₹) 4.41 6.83 4.24 0.44 2.84 - -
Operating Margin (%) 21.0% 19.0% 18.0% 8.0% 15.0% - -

TATVA Share Price Trend — 1-Year Movement Across Quarterly Results

Tatva Chintan Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check Tatva Chintan Pharma market worth to track the company's total market size over time.

Profitability Ratios

Profit Margin 7.5%
EBITDA Margin 20.9%
Operating Margin 21.0%
ROE (Annual) 5.1%

Balance Sheet Highlights

Total Assets ₹1,004 Cr
Total Equity ₹782 Cr
Current Assets ₹350 Cr
Current Liabilities ₹9 Cr

Cash Flow Analysis

Operating Cash Flow ₹32 Cr
Investing Cash Flow ₹-116 Cr
Financing Cash Flow ₹79 Cr
Net Cash Flow ₹-6 Cr

Current Market Data

Current Price ₹1799.00
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 109
Sept 2025 125
Jun 2026 170
Mar 2026 134

Net Profit Trend (₹ Cr)

Mar 2025 1
Sept 2025 10
Jun 2026 16
Mar 2026 10

Operating Margin Trend (%)

Mar 2025 8.0%
Sept 2025 18.0%
Jun 2026 19.0%
Mar 2026 21.0%

TATVA vs Chemicals Peers — Quarterly Revenue, Profit & Market Cap

Tatva Chintan Pharma latest quarter revenue and net profit vs Chemicals competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Pidilite Industries
Mar 2026 		₹149,017.59 Cr 1487.7 3,648 584 -21.7% - 16.0% 261.5
SRF
Mar 2026 		₹73,697.14 Cr 2460.0 4,557 582 -8.4% - 12.8% 125.3
Linde
Mar 2026 		₹53,281.32 Cr 6041.0 621 77 -11.5% - 12.4% 665.3
Coromandel Internat…
Mar 2026 		₹52,036.94 Cr 1801.4 6,068 115 -26.1% - 1.9% 379.2
Gujarat Fluorochemi…
Mar 2026 		₹50,280.54 Cr 4429.8 1,375 100 -14.1% - 7.3% 446.6
Sector Quarterly Performance Comparison
Chemicals sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores